Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical has entered into an agreement with Valeant Pharmaceuticals to promote the antiemetic drug Cesamet in the US. Cesamet is a cannabinoid agonist for the treatment of chemotherapy-induced emesis.
Subscribe to our email newsletter
Under the terms of the agreement, Par will promote Cesamet to physicians in the US, whilst Valeant will record sales of the drug and fund all marketing expenses associated with the product.
Valeant has received an approvable letter from the FDA for Cesamet and is awaiting final approval. The company acquired the drug from Eli Lilly & Company in 2004 and currently markets the product in Canada where the drug now holds approximately 85% share of total prescriptions in the Canadian cannabinoid market.
“We look forward to a very successful collaboration with Par,” said Wesley Wheeler, president of Valeant Pharmaceuticals North America. “Cesamet is a drug that will address an important and unmet medical need for many patients. Its rapid adoption in Canada clearly demonstrates the product’s utility.”